DARPA's June 3 Quadruple: Four BTO SBIRs That Sketch the Future of Distributed Battlefield Medicine

The Defense Advanced Research Projects Agency's Biological Technologies Office does not normally release SBIR topics in clusters. Most months of the year, BTO operates on the same staggered cadence as the rest of DARPA — one or two topics released in pre-release on the first Wednesday of the month at defensesbirsttr.mil, opening for proposals a few weeks later. The early-summer 2026 release is different. Four topics opened on May 6, 2026 with a single, simultaneous close date of June 3, 2026, and the technical scope of those four topics, read together, is more coherent than the BTO portfolio normally appears in any given month.

The topics are SWiFT (Smart Whole Blood Field Transfusion system), BARK (Broadening Availability of Regimens for K-9s), EXPOSITION (Extremity Platform for On-Demand Surgical Implantation and Tissue Integration with Osteochondral Neogenesis), and Medical Swarm Robotics for Extraction and Life-Saving Interventions. Each one is a distinct technical bet. Read together, they sketch the operating concept of the forward-deployed casualty care environment that DARPA is preparing to send into combat in the back half of this decade — distributed across smaller medical footprints, capable of operating on humans and military working dogs alike, biologically autonomous in the sense that it can manufacture or regenerate critical inputs in place, and increasingly mediated by robotic and AI systems that move faster than human medics.

For small business technology developers in the biomedical, robotics, and biomaterials sectors, the simultaneous June 3 close is the most consequential set of DARPA medical SBIR opportunities of 2026.

What's in the cluster

The four topics differ in technical maturity, funding ceiling, and proposal structure.

SWiFT is the most technically advanced of the four. The topic seeks a smart whole blood transfusion system that operates in the field — the kind of capability that today requires a forward surgical team with refrigeration, typed blood inventory, and trained personnel to administer. Phase I awards are $300,000; Phase II awards are up to $1.8 million; and the topic includes a Direct-to-Phase II option of $1.5 million for companies with prior feasibility work to skip directly to prototype development. The Direct-to-Phase II option is a meaningful signal — DARPA only structures topics this way when it believes there is a credible pool of existing technical work, often from prior DoD grants or private investment, that can move directly to engineering development. (Granted's earlier deep dive on SWiFT covers the underlying powdered and synthetic blood program in detail.)

BARK is the dual-species topic. As covered in Granted's deep dive on the K-9 medical program, the goal is medical products that function for both humans and military working dogs — plasma filters, universal synthetic plasma, dual-species monitoring sensors, adjustable splints and ventilators, and pharmaceuticals with modulated dosing across species. Phase I is $150,000 and Phase II is $1.3 million, the lowest funding envelope of the four. Phase I prohibits human and animal subject research, so feasibility work proceeds entirely through in vitro, in silico, and modeling-based approaches.

EXPOSITION is a Direct-to-Phase II only topic at $1.5 million. It targets osteochondral neogenesis — the regeneration of cartilage and underlying bone in damaged extremity joints — through a surgically implantable platform that integrates with native tissue and enables on-demand reconstruction in field surgical settings. This is one of the most ambitious topics DARPA has released in the regenerative medicine space in recent years, and the Direct-to-Phase II structure indicates that the agency is looking for performers with existing tissue engineering or biomaterials platforms ready to adapt to extremity reconstruction, not feasibility studies of the underlying biology.

Medical Swarm Robotics for Extraction and Life-Saving Interventions is the wildest card of the four. Phase I awards are $300,000 and Phase II awards are up to $1.5 million for the development of distributed robotic systems capable of casualty extraction and forward intervention without human medic involvement at the point of injury. This is the topic where DARPA is most openly speculative about the eventual concept of operations, and it is also the topic with the broadest potential applicant pool — robotics firms, autonomy startups, and medical device companies can all credibly propose.

The combined ceiling, if a single company were positioned to compete on all four, exceeds $1 million in Phase I awards and $6.1 million in Phase II awards. No realistic company will compete on all four. But many credible applicants can compete on two — most plausibly SWiFT plus BARK (dual-species hematology) or EXPOSITION plus Medical Swarm Robotics (surgical autonomy plus distributed delivery).

What ties them together

The four topics are not a random selection from the BTO portfolio. They share a common operational concept that has been emerging in DARPA's combat casualty care strategy for the last three years and is now appearing across SBIR, BAA, and seedling programs more explicitly.

The operating concept assumes that future combat will look less like Operation Enduring Freedom — large forward operating bases with Role 2 and Role 3 surgical facilities, golden-hour evacuation chains, and trauma centers waiting downstream — and more like distributed operations in contested logistics environments where forward medical infrastructure is small, mobile, and intermittently connected. In that environment, the casualty care system needs to (1) generate blood and other consumables in place, (2) work for non-human force assets like military working dogs, (3) accomplish reconstructive procedures forward of the traditional Role 2 surgical capability, and (4) leverage robotic systems for tasks that would otherwise require human medics to expose themselves to fire.

SWiFT handles input generation. BARK handles species interoperability. EXPOSITION handles forward reconstruction. Medical Swarm Robotics handles distributed extraction and intervention. Each one is a partial answer to the same logistics problem, and together they cover most of the surface area that DARPA's combat casualty care strategy is trying to address.

This coherence matters for proposal positioning. Applicants who can demonstrate in their commercialization narratives that they understand how their topic fits into the broader operational concept — and who can identify Phase III transition pathways that ride on the operational concept rather than just the topic — will score higher in review. DARPA program managers in BTO are increasingly explicit about wanting performers who can articulate the operating concept, not just the technology.

What the funding mechanism implies

The use of the SBIR vehicle for four such ambitious topics is itself a strategic signal. DARPA could have run any of these as a Broad Agency Announcement, a seedling, or a directed contract to an established prime. It chose SBIR for all four. The implication is that the agency believes the most promising performers are small businesses — startups, university spinouts, and small biomedical and robotics firms — rather than the traditional DoD medical contracting base.

This is consistent with the broader 2026 SBIR/STTR reauthorization environment (covered in detail in Granted's analysis of the $30 million Strategic Breakthrough Awards), which raised funding ceilings, expanded national security vetting, and pushed agencies to make commercialization more central to program selection. The DARPA BTO June 3 cluster is one of the first concrete tests of how those reauthorization changes show up in practice. Companies that build credible commercialization narratives — particularly ones that identify civilian dual-use applications in emergency medicine, veterinary care, sports medicine, or robotic-assisted surgery — will perform better in evaluation than companies that pitch pure defense applications.

How to compete on a 28-day clock

The window between the May 6, 2026 open date and the June 3, 2026 close is 28 days. That is short. For a typical Phase I proposal, 28 days requires that the prior research, team, letters of support, and commercialization plan are already substantially in place. The companies most likely to win these awards are not the ones starting their proposals on May 6 — they are the ones who began technical preparation in April based on the pre-release.

Three operational steps make a meaningful difference in the remaining window.

First, lock the technical approach by May 20. A proposal that goes through more than one fundamental technical pivot inside the final two weeks rarely reads well in review. DARPA evaluators are looking for a clear, defensible, technically specific approach — not a menu of options.

Second, secure letters of support from prospective Phase III transition partners. The single best signal of commercialization viability in a DARPA proposal is a letter from a defense or commercial partner committing to evaluation, integration, or procurement on a defined timeline. For SWiFT, that might be a Role 2 medical training organization. For BARK, the Military Working Dog Program or a civilian veterinary network. For EXPOSITION, a sports medicine orthopedic clinic. For Medical Swarm Robotics, a casualty evacuation training command or a hospital trauma center.

Third, submit through the DSIP portal early enough to handle technical problems. The Defense SBIR/STTR Innovation Portal has historically encountered traffic-induced submission delays in the final 24 hours before close. The professional rule of thumb is to complete submission no later than 48 hours before the deadline. For a June 3 close, that means a final upload on June 1.

The June 3 quadruple is not the largest DARPA SBIR release of 2026, nor the one with the highest individual funding ceilings. But it is the cluster that most clearly reveals where the agency's medical strategy is heading, and the small businesses that win one or two of these topics will be positioned to ride that strategy through Phase II and into the Phase III transitions that the SBIR/STTR reauthorization framework is now built to accelerate.